Cargando…

Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer

Ivosidenib is an isocitrate dehydrogenase mutant inhibitor that the US Food and Drug Administration recently approved for the treatment of leukemia. Studies suggested that ivosidenib may inhibit the progression of non-small cell lung cancer (NSCLC). In the present study, we explored RNAs and their p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Juan, Chen, Ru, Shen, Huiqing, Yan, Ting, Qian, Yu, Zhang, Yaping, Huang, Zhuoya, Kong, Pengzhou, Pang, Min, Zhang, Xinri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042334/ https://www.ncbi.nlm.nih.gov/pubmed/33859940 http://dx.doi.org/10.3389/fonc.2021.626605

Ejemplares similares

Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer
por: Chen, Ru, et al.
Publicado: (2021)

Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Cyclovirobuxine D inhibits growth and progression of non-small cell lung cancer cells by suppressing the KIF11-CDC25C-CDK1-CyclinB1 G(2)/M phase transition regulatory network and the NFκB/JNK signaling pathway
por: Xue, Ting, et al.
Publicado: (2023)

Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Correction to: Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer
por: Kong, Pengzhou, et al.
Publicado: (2022)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
por: Sumbly, Vikram, et al.
Publicado: (2022)

PIF1 Promotes Autophagy to Inhibit Chronic Hypoxia Induced Apoptosis of Pulmonary Artery Endothelial Cells
por: Zhao, Yujing, et al.
Publicado: (2023)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

P441: CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB
por: Watts, Justin M., et al.
Publicado: (2023)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence
por: Zhang, Chuan-long, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
por: Shen, Qian, et al.
Publicado: (2021)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer, Galia, et al.
Publicado: (2021)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

Combined early palliative care for non-small-cell lung cancer patients: a randomized controlled trial in Chongqing, China
por: Chen, Mengting, et al.
Publicado: (2023)

Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway
por: Huang, Ma-Sha, et al.
Publicado: (2019)

Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer
por: Shen, Qinglin, et al.
Publicado: (2023)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
por: Zhao, Jiangang, et al.
Publicado: (2020)

A Propensity-Matched Analysis of Survival of Clinically Diagnosed Early-Stage Lung Cancer and Biopsy-Proven Early-Stage Non-Small Cell Lung Cancer Following Stereotactic Ablative Radiotherapy
por: Zhang, Ran, et al.
Publicado: (2021)

The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation
por: Xu, Kandi, et al.
Publicado: (2021)

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer
por: He, Ru, et al.
Publicado: (2019)

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
por: Fan, Bin, et al.
Publicado: (2019)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
por: Reinbold, Raphael, et al.
Publicado: (2022)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
por: Liang, Xiuju, et al.
Publicado: (2019)

Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
por: Huffman, Kenneth E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6037780mm2ovvgc9oldgts1nrj